As filed with the Securities and Exchange Commission on July 23, 2024
Commission File No. 333-280300
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST EFFECTIVE AMENDMENT NO. 1
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
OptimizeRx Corporation | ||
(Exact name of registrant as specified in its charter) | ||
Nevada | 26-1265381 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
260 Charles Street, Suite 302, Waltham, MA | 02453 | |
(Address of Principal Executive Offices) | (Zip Code) | |
OptimizeRx Corporation 2021 Equity Incentive Plan | ||
(Full title of the plan) | ||
Marion Odence-Ford, Esquire General Counsel OptimizeRx Corporation 260 Charles Street Suite 302 Waltham, MA 02453 (248) 651-6568 | ||
(Name and address of agent for service) | ||
(Telephone number, including area code, of agent for service) | ||
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
Emerging growth company | ☐ | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Explanatory Note
OptimizeRx Corporation (the “Company”) hereby amends its original Registration Statement on Form S-8 (File No. 333-280300) filed with the Securities and Exchange Commission (the “Commission”) on June 18, 2024 (the “Original Filing”) solely for the purpose of updating the exhibit index to include Exhibit 23.3 and to file Exhibit 23.3. Exhibit 23.3 is the consent of UHY LLP related to the financial statements of Healthy Offers, Inc. as of December 31, 2022 and 2021 and for the years then ended (the “Auditor’s Consent”). The Auditor’s Consent was inadvertently omitted from the Original Filing. This filing is being made solely to update the exhibit index and provide the Auditor’s Consent and does not update, amend, or modify any other information, statement or disclosure contained in or filed with the Original Filing.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The following exhibits are filed as part of this Registration Statement or, where so indicated have been previously filed and are incorporated herein by reference.
* | Previously filed with Original Filing. |
II-1
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts on July 23, 2024.
OptimizeRx Corporation | ||
By: | /s/ William J. Febbo | |
Name: | William J. Febbo | |
Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated.
Signature | Title | Date | ||
/s/ William J. Febbo | Chief Executive Officer and Director | July 23, 2024 | ||
William J. Febbo | (Principal Executive Officer) | |||
/s/ Edward Stelmakh | Chief Financial Officer and Chief Operations Officer | July 23, 2024 | ||
Edward Stelmakh | (Principal Financial and Accounting Officer) | |||
* | Director, Chairperson | July 23, 2024 | ||
Lynn O’Connor Vos | ||||
* | Director | July 23, 2024 | ||
James Lang | ||||
* | Director | July 23, 2024 | ||
Patrick Spangler | ||||
* | Director | July 23, 2024 | ||
Gregory D. Wasson | ||||
* | Director | July 23, 2024 | ||
Catherine M. Klema |
*By: | /s/ William J. Febbo | |
William J. Febbo | ||
Attorney-in-Fact |
II-2